Search

Your search keyword '"Khadka, Sushmita"' showing total 17 results
Start Over Author "Khadka, Sushmita" Publication Year Range Last 3 years
17 results on '"Khadka, Sushmita"'

1. Cardiac events after standard of care idecabtagene vicleucel for relapsed and refractory multiple myeloma

Author

Lee, Dae Hyun, Kumar, Abhishek, Mohammed, Turab, Peres, Lauren C., Alsina, Melissa, Bachmeier, Christina, Blue, Brandon J., Brayer, Jason, Chandrasekhar, Sanjay, Grajales Cruz, Ariel, De Avila, Gabe, Elmariah, Hany, Faramand, Rawan, Freeman, Ciara, Jain, Michael, Khadka, Sushmita, Khimani, Farhad, Liu, Hien, Nishihori, Taiga, Oswald, Laura B., Castaneda Puglianini, Omar A., Shain, Kenneth H., Smith, Eric, Baz, Rachid C., Locke, Frederick L., Oliveira, Guilherme H., Alomar, Mohammed, and Hansen, Doris K.

Published
2023
Full Text
View/download PDF

2. Autologous Hematopoietic Cell Transplantation Consolidation for First Response is Associated With Longer Survival Among Patients With Nodal Peripheral T Cell Lymphoma

Author

Zhang, Yumeng, Rose, Ashley, Khadka, Sushmita, Cao, Biwei, Eatrides, Jennifer, Saeed, Hayder, Shah, Bijal D., Chavez, Julio, Bello, Celeste, Lazaryan, Aleksandr, Khimani, Farhad, Ibarz, Javier Pinilla, Liu, Hien D., Locke, Frederick L., Jain, Michael D., Zhang, Ling, Kharfan-Dabaja, Mohamed A., Kim, Jongphil, Ayala, Ernesto, Nishihori, Taiga, and Sokol, Lubomir

Published
2024
Full Text
View/download PDF

3. Effect of talquetamab on responses in patients with relapsed and refractory multiple myeloma with prior exposure to T-cell directed therapies.

Author

Graeter, Allison, primary, Castaneda Puglianini, Omar Alexis, additional, Hansen, Doris K., additional, Vazquez-Martinez, Mariola A., additional, Blue, Brandon Jamaal, additional, Khadka, Sushmita, additional, Liu, Hien, additional, Ochoa-Bayona, Jose L., additional, Freeman, Ciara L., additional, Locke, Frederick L, additional, Nishihori, Taiga, additional, Shain, Kenneth H., additional, Baz, Rachid C., additional, Alsina, Melissa, additional, and Grajales-Cruz, Ariel Felipe, additional

Published
2024
Full Text
View/download PDF

4. Disparities in Outcomes of Hospitalizations Due to Multiple Myeloma: A Nationwide Comparison

Author

Khadka, Sushmita, primary, Balaji, Swetha, additional, Kaur, Japjeet, additional, Solanki, Dhanshree, additional, Kasianchyk, Mariia, additional, Chowdhury, Humayra, additional, Patel, Ishani, additional, Qasim, Muhammad, additional, Desai, Maheshkumar, additional, Maiyani, Prakash, additional, Moradiya, Dharmeshkumar V, additional, Lal, Darshan, additional, Patel, Achint A, additional, and Lekkala, Manidhar, additional

Published
2023
Full Text
View/download PDF

5. PB2092: INCIDENCE AND RISK FACTORS ASSOCIATED WITH BLEEDING FOLLOWING ANTI-B CELL MATURATION ANTIGEN CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA

Author

Mohammed, Turab, primary, Shahzad, Moazzam, additional, Peres, Lauren, additional, Khadka, Sushmita, additional, Colinleitzinger, Christelle, additional, Babu, Abida, additional, Doyle, William, additional, Puglianini, Omar Castaneda, additional, Oswald, Laura, additional, De Avila, Gabe, additional, Grajales-Cruz, Ariel, additional, Blue, Brandon, additional, Ochoa-Bayona, Jose, additional, Smith, Eric, additional, Corallo, Salvatore, additional, Khimani4, Farhad, additional, Faramand, Rawan, additional, Elmariah, Hany, additional, Lazaryan, Aleksandr, additional, Jain, Michael, additional, Liu, Hien, additional, Nishihori, Taiga, additional, Shain, Ken, additional, Baz, Rachid, additional, Alsina, Melissa, additional, Locke, Frederick, additional, Freeman, Ciara, additional, and Hansen, Doris, additional

Published
2023
Full Text
View/download PDF

16. Teclistamab Induces Favorable Responses in Patients with Relapsed and Refractory Multiple Myeloma after Prior BCMA-Directed Therapy

Author

Grajales-Cruz, Ariel F., Castaneda, Omar, Hansen, Doris K., Vazquez-Martinez, Mariola A, Blue, Brandon, Khadka, Sushmita, Liu, Hien, Ochoa-Bayona, Jose L., Freeman, Ciara Louise L., Locke, Frederick L., Nishihori, Taiga, Shain, Kenneth, Baz, Rachid, and Alsina, Melissa

Abstract

Introduction: Teclistamab (TEC) received regulatory approval for the treatment of patients with Relapsed/Refractory Multiple Myeloma (RRMM) after ≥ 3 prior lines of therapy based on the results of the pivotal MajesTEC-1 trial in which such patients achieved an overall response rate (ORR) of 63%, ≥ complete response (CR) of 39%, and median progression free survival (PFS) of 11.3 months (Moreau et al. N Engl J Med2022). Patients who had received a prior B-cell maturation antigen-targeted therapy (BCMA-TT) were excluded from MajesTEC-1 trial. Data on the efficacy of TEC in patients who have received and relapsed after prior BCMA targeted therapy is lacking. Several studies have shown reduced efficacy of both FDA approved BCMA targeted chimeric antigen receptor T cell therapies (CAR-T) for myeloma, idecabtagene vicleucel (ide-cel) and ciltacabtagene autoleucel (cilta-cel), when administered after BCMA targeted bi-specific antibodies. There is a paucity of data on the efficacy of TEC when administered in patients who progress after ide-cel or cilta-cel. We evaluated the real-world outcomes of patients treated with standard of care (SOC) TEC after having previously received a BCMA-TT.

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results